XLONDEST
Market cap3mUSD
Aug 12, Last price
3.00GBP
Name
Destiny Pharma PLC
Chart & Performance
P/E
—
P/S
345.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.69%
Rev. gr., 5y
%
Revenues
832k
+438.22%
Net income
-6m
L-13.02%
CFO
-5m
L-11.03%
Earnings
Apr 23, 2025
Profile
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 832 438.22% | 154 14.42% | 135 984.56% | |||||||
Cost of revenue | 9,334 | 7,886 | 6,434 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (8,503) | (7,732) | (6,299) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (789) | (1,208) | (932) | |||||||
Tax Rate | ||||||||||
NOPAT | (7,714) | (6,524) | (5,367) | |||||||
Net income | (5,657) -13.02% | (6,504) 21.80% | (5,339) -1.32% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,745 | 6,086 | 7 | |||||||
BB yield | -10.63% | -16.21% | -0.01% | |||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (6,383) | (4,903) | (4,646) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (5,185) | (5,827) | (5,075) | |||||||
CAPEX | (81) | (1) | (30) | |||||||
Cash from investing activities | (81) | (1) | (30) | |||||||
Cash from financing activities | 6,745 | 6,086 | 7 | |||||||
FCF | (7,788) | (6,383) | (5,538) | |||||||
| Balance | ||||||||||
Cash | 6,383 | 4,903 | 4,646 | |||||||
Long term investments | ||||||||||
Excess cash | 6,341 | 4,896 | 4,639 | |||||||
Stockholders' equity | (30,379) | (25,418) | (19,582) | |||||||
Invested Capital | 39,569 | 32,963 | 27,009 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 90,671 | 70,201 | 59,868 | |||||||
Price | 0.70 30.84% | 0.54 -49.05% | 1.05 53.28% | |||||||
Market cap | 63,470 68.99% | 37,558 -40.25% | 62,861 102.88% | |||||||
EV | 57,087 | 32,654 | 58,216 | |||||||
EBITDA | (8,497) | (7,719) | (6,286) | |||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||